• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

解析 E1 修复受损心肌细胞:治疗意义及 H-FABP 作为心血管疾病和全身炎症的检测指标。

Resolvin E1 heals injured cardiomyocytes: Therapeutic implications and H-FABP as a readout for cardiovascular disease & systemic inflammation.

机构信息

Boston University, United States of America.

Boston University School of Medicine, United States of America.

出版信息

Prostaglandins Leukot Essent Fatty Acids. 2023 Oct;197:102586. doi: 10.1016/j.plefa.2023.102586. Epub 2023 Aug 10.

DOI:10.1016/j.plefa.2023.102586
PMID:37604082
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11203388/
Abstract

The purpose of this study is to investigate heart-fatty acid binding protein (H-FABP) leakage from cardiomyocytes as a quantitative measure of cell membrane damage and to test healing by Resolvin E1 (RVE1) as a potential therapeutic for patients with inflammatory diseases (cardiovascular disease and comorbidities) with high morbidity and mortality. Our quantitative ELISA assays demonstrated H-FABP as a sensitive and reliable biomarker for measuring cardiomyocyte damage induced by lipopolysaccharide (LPS) and healing by RvE1, a specialized pro-resolving mediator (SPM) derived from the Omega-3 fatty acid, eicosapentaenoic acid (EPA), a dietary nutrient that balances inflammation to restore homeostasis. RvE1 reduced leakage of H-FABP by up to 86%, which supports our hypothesis that inflammation as a mechanism of injury can be targeted for therapy. H-FABP as a blood biomarker was tested in 40 patients admitted to Boston Medical Center for respiratory distress, (20 patients with and 20 patients without COVID infection). High levels of H-FABP correlated with clinically diagnosed CVD, diabetes, and end-stage renal disease (ESRD) in both patient groups. The level of H-FABP indicates not only CVD damage but is a valuable measure for patients with increased inflammation disease comorbidities.

摘要

本研究旨在探讨心肌细胞中心脂肪酸结合蛋白(H-FABP)的渗漏情况,将其作为细胞膜损伤的定量指标,并通过 Resolvin E1(RVE1)的修复作用来测试其对患有炎症性疾病(心血管疾病和合并症)的患者的潜在治疗作用,此类患者具有高发病率和死亡率。我们的定量 ELISA 检测表明 H-FABP 是一种敏感且可靠的生物标志物,可用于测量脂多糖(LPS)诱导的心肌细胞损伤和 RvE1 的修复作用,RvE1 是一种来源于ω-3 脂肪酸二十碳五烯酸(EPA)的特殊促解决介质(SPM),是一种可平衡炎症、恢复体内平衡的膳食营养物。RvE1 可使 H-FABP 的渗漏减少多达 86%,这支持了我们的假设,即炎症作为一种损伤机制可以作为治疗的靶点。我们在因呼吸窘迫而入住波士顿医疗中心的 40 名患者中对 H-FABP 作为血液生物标志物进行了测试,(其中 20 名患者患有 COVID 感染,20 名患者未患有 COVID 感染)。在这两组患者中,H-FABP 水平与临床诊断的心血管疾病、糖尿病和终末期肾病(ESRD)均相关。H-FABP 水平不仅表明了心血管疾病的损害,而且是衡量炎症性疾病合并症患者的重要指标。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afba/11203388/09e811bb0c1c/nihms-2000821-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afba/11203388/692d8aa9892f/nihms-2000821-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afba/11203388/f9800730804a/nihms-2000821-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afba/11203388/41e1a016a94e/nihms-2000821-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afba/11203388/6fec2b4fb114/nihms-2000821-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afba/11203388/fc02fb7f4272/nihms-2000821-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afba/11203388/09e811bb0c1c/nihms-2000821-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afba/11203388/692d8aa9892f/nihms-2000821-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afba/11203388/f9800730804a/nihms-2000821-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afba/11203388/41e1a016a94e/nihms-2000821-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afba/11203388/6fec2b4fb114/nihms-2000821-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afba/11203388/fc02fb7f4272/nihms-2000821-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afba/11203388/09e811bb0c1c/nihms-2000821-f0006.jpg

相似文献

1
Resolvin E1 heals injured cardiomyocytes: Therapeutic implications and H-FABP as a readout for cardiovascular disease & systemic inflammation.解析 E1 修复受损心肌细胞:治疗意义及 H-FABP 作为心血管疾病和全身炎症的检测指标。
Prostaglandins Leukot Essent Fatty Acids. 2023 Oct;197:102586. doi: 10.1016/j.plefa.2023.102586. Epub 2023 Aug 10.
2
Resolvin E1 protects the rat heart against reperfusion injury.解析素 E1 可保护大鼠心脏免受再灌注损伤。
Am J Physiol Heart Circ Physiol. 2010 Jul;299(1):H153-64. doi: 10.1152/ajpheart.01057.2009. Epub 2010 Apr 30.
3
Resolvin D1 and E1 promote resolution of inflammation in rat cardiac fibroblast in vitro.解析素 D1 和 E1 促进大鼠心肌成纤维细胞炎症消退的体外研究。
Mol Biol Rep. 2021 Jan;48(1):57-66. doi: 10.1007/s11033-020-06133-8. Epub 2021 Jan 18.
4
[Protective effect of heart-fatty acid binding protein on lipopolysaccharide-induced cardiomyocyte damage].心脏脂肪酸结合蛋白对脂多糖诱导的心肌细胞损伤的保护作用
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2015 May;40(5):457-63. doi: 10.11817/j.issn.1672-7347.2015.05.001.
5
E-series resolvin metabolome, biosynthesis and critical role of stereochemistry of specialized pro-resolving mediators (SPMs) in inflammation-resolution: Preparing SPMs for long COVID-19, human clinical trials, and targeted precision nutrition.E 系列消退素代谢组、专门的促消退介质(SPM)的生物合成及其立体化学在炎症消退中的关键作用:为长期新冠、人体临床试验和靶向精准营养制备 SPM。
Semin Immunol. 2022 Jan;59:101597. doi: 10.1016/j.smim.2022.101597. Epub 2022 Feb 16.
6
Resolvin D1 and E1 promote resolution of inflammation in microglial cells in vitro.解析素 D1 和 E1 促进体外小胶质细胞炎症消退。
Brain Behav Immun. 2016 Jul;55:249-259. doi: 10.1016/j.bbi.2015.12.013. Epub 2015 Dec 21.
7
Resolvin E1 Regulates Th17 Function and T Cell Activation.解析素 E1 调节 Th17 功能和 T 细胞激活。
Front Immunol. 2021 Mar 17;12:637983. doi: 10.3389/fimmu.2021.637983. eCollection 2021.
8
Resolvin E1 accelerates pulp repair by regulating inflammation and stimulating dentin regeneration in dental pulp stem cells.解析素 E1 通过调节炎症反应和刺激牙髓干细胞分化牙本质来加速牙髓修复。
Stem Cell Res Ther. 2021 Jan 22;12(1):75. doi: 10.1186/s13287-021-02141-y.
9
Early treatment with Resolvin E1 facilitates myocardial recovery from ischaemia in mice.Resolvin E1 的早期治疗可促进小鼠缺血心肌的恢复。
Br J Pharmacol. 2018 Apr;175(8):1205-1216. doi: 10.1111/bph.14041. Epub 2017 Oct 22.
10
Pro-Resolving Mediator Resolvin E1 Restores Alveolar Fluid Clearance in Acute Respiratory Distress Syndrome.促消退介质RvE1可恢复急性呼吸窘迫综合征中的肺泡液体清除功能。
Shock. 2022 Apr 1;57(4):565-575. doi: 10.1097/SHK.0000000000001865.

引用本文的文献

1
The Link between Lipids and Inflammation: Focus on Targeting Sialidase Activity as a Novel Strategy for Anti-Atherosclerotic Therapy.脂质与炎症之间的联系:聚焦于靶向唾液酸酶活性作为抗动脉粥样硬化治疗的新策略。
Curr Med Chem. 2025;32(15):2887-2898. doi: 10.2174/092986733215250325111534.
2
Dynamics of Fatty Acid Composition in Lipids and Their Distinct Roles in Cardiometabolic Health.脂质中脂肪酸组成的动态变化及其在心脏代谢健康中的独特作用。
Biomolecules. 2025 May 10;15(5):696. doi: 10.3390/biom15050696.

本文引用的文献

1
Severe COVID-19 outcomes by cardiovascular risk profile in England in 2020: a population-based cohort study.2020年英格兰地区按心血管风险状况划分的重症新型冠状病毒肺炎结局:一项基于人群的队列研究。
Lancet Reg Health Eur. 2023 Apr;27:100604. doi: 10.1016/j.lanepe.2023.100604. Epub 2023 Mar 7.
2
Circulating Spike Protein Detected in Post-COVID-19 mRNA Vaccine Myocarditis.新冠病毒 mRNA 疫苗心肌炎患者循环 Spike 蛋白的检测。
Circulation. 2023 Mar 14;147(11):867-876. doi: 10.1161/CIRCULATIONAHA.122.061025. Epub 2023 Jan 4.
3
Cardiovascular Drug Interactions With Nirmatrelvir/Ritonavir in Patients With COVID-19: JACC Review Topic of the Week.
心血管药物相互作用与尼马曲韦/利托那韦在 COVID-19 患者中的应用:JACC 综述专题的一周。
J Am Coll Cardiol. 2022 Nov 15;80(20):1912-1924. doi: 10.1016/j.jacc.2022.08.800. Epub 2022 Oct 12.
4
Resolvin E1 Reduces Tumor Growth in a Xenograft Model of Lung Cancer.解析 E1 可减少肺癌移植瘤模型中的肿瘤生长。
Am J Pathol. 2022 Oct;192(10):1470-1484. doi: 10.1016/j.ajpath.2022.07.004. Epub 2022 Aug 6.
5
The COVID Heart-One Year After SARS-CoV-2 Infection, Patients Have an Array of Increased Cardiovascular Risks.新冠之心——SARS-CoV-2感染一年后,患者面临一系列心血管风险增加的情况。
JAMA. 2022 Mar 22;327(12):1113-1114. doi: 10.1001/jama.2022.2411.
6
Hundreds of COVID trials could provide a deluge of new drugs.数百项新冠试验可能会带来大量新药。
Nature. 2022 Mar;603(7899):25-27. doi: 10.1038/d41586-022-00562-0.
7
Long-term cardiovascular outcomes of COVID-19.COVID-19 长期心血管后果。
Nat Med. 2022 Mar;28(3):583-590. doi: 10.1038/s41591-022-01689-3. Epub 2022 Feb 7.
8
Potential therapeutic options for COVID-19: an update on current evidence.针对 COVID-19 的潜在治疗选择:当前证据的更新。
Eur J Med Res. 2022 Jan 13;27(1):6. doi: 10.1186/s40001-021-00626-3.
9
Anti-Inflammatory Function of Fatty Acids and Involvement of Their Metabolites in the Resolution of Inflammation in Chronic Obstructive Pulmonary Disease.脂肪酸的抗炎功能及其代谢物在慢性阻塞性肺疾病炎症消退中的作用。
Int J Mol Sci. 2021 Nov 26;22(23):12803. doi: 10.3390/ijms222312803.
10
Increased LPS levels coexist with systemic inflammation and result in monocyte activation in severe COVID-19 patients.严重 COVID-19 患者的 LPS 水平升高与全身炎症并存,并导致单核细胞活化。
Int Immunopharmacol. 2021 Nov;100:108125. doi: 10.1016/j.intimp.2021.108125. Epub 2021 Sep 9.